How should medicines reimbursement work? The views of Spanish experts
Saved in:
| Title: | How should medicines reimbursement work? The views of Spanish experts |
|---|---|
| Authors: | Juan Carlos Rejon-Parrilla, David Epstein, Daniel Pérez-Troncoso, Jaime Espin |
| Contributors: | [Rejon-Parrilla,JC] Health Technology Assessment Area (AETSA), Andalusian Public Foundation Progress and Health (FPS), Seville, Spain., [Espín,J] Andalusian School of Public Health, Granada, Spain., [Espín,J] Instituto de Investigación Biosanitaria ibs., Granada, Spain., [Espín,J] CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain., Spanish Ministry of Science and Innovation/National Research Agency MCIN/AEI/10.13039/501100011033 |
| Source: | RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía instname Health Economics, Policy and Law, Pp 1-18 |
| Publisher Information: | Cambridge University Press (CUP), 2025. |
| Publication Year: | 2025 |
| Subject Terms: | Technology Assessment, Biomedical, Pharmaceutical Services, Cost-Benefit Analysis, pharmaceutical policy, health technology assessment, Economics, Pharmaceutical, Public aspects of medicine, RA1-1270, Evaluación de la Tecnología Biomédica, pricing and reimbursement, Economía Farmacéutica, Servicios Farmacéuticos |
| Description: | Although the criteria that support reimbursement decisions for medicines are often set by legislation, as is the case in Spain, in many cases neither the definition nor the measurement methods for these criteria are provided. Our goal was to elicit the views of a large sample of Spanish technical specialists on how to evaluate each one of the criteria that inform pricing and reimbursement decisions in Spain. Professionals from various stakeholder groups involved in health economics, health technology assessment, and industry participated in a survey. Participants recommended that reimbursement decisions should take specific account of unmet medical need and rare diseases. Health benefit should be measured using quality-adjusted life-years. There should be an explicit cost-effectiveness threshold, and this threshold should take account of population groups and special situations. |
| Document Type: | Article |
| File Description: | application/pdf |
| Language: | English |
| ISSN: | 1744-134X 1744-1331 |
| DOI: | 10.1017/s174413312400029x |
| Access URL: | https://hdl.handle.net/10668/28518 https://doaj.org/article/ded131cbb0d1496e8ad450f837b251c7 |
| Rights: | CC BY |
| Accession Number: | edsair.doi.dedup.....5e0bc9e4b0b245a9776e897e680459ac |
| Database: | OpenAIRE |
Nájsť tento článok vo Web of Science | Abstract: | Although the criteria that support reimbursement decisions for medicines are often set by legislation, as is the case in Spain, in many cases neither the definition nor the measurement methods for these criteria are provided. Our goal was to elicit the views of a large sample of Spanish technical specialists on how to evaluate each one of the criteria that inform pricing and reimbursement decisions in Spain. Professionals from various stakeholder groups involved in health economics, health technology assessment, and industry participated in a survey. Participants recommended that reimbursement decisions should take specific account of unmet medical need and rare diseases. Health benefit should be measured using quality-adjusted life-years. There should be an explicit cost-effectiveness threshold, and this threshold should take account of population groups and special situations. |
|---|---|
| ISSN: | 1744134X 17441331 |
| DOI: | 10.1017/s174413312400029x |